Back to Search
Start Over
Biologic NMEs Maintain Strong Presence in 2017 Drug Approvals: Biologic new molecular entities (NMEs) accounted for 26% of total NME approvals in 2017
- Source :
- Biopharm International. March, 2018, Vol. 31 Issue 3, p14, 3 p.
- Publication Year :
- 2018
-
Abstract
- FDA had another banner year for new molecular entity (NME) drug approvals with 46 NMEs approved by the agency's Center for Drug Evaluation and Research (CDER) in 2017 (1), compared [...]
- Subjects :
- United States. Food and Drug Administration
United States. Center for Drug Evaluation and Research
Regeneron Pharmaceuticals Inc. -- Forecasts and trends
AstraZeneca PLC -- Forecasts and trends
Sanofi S.A. -- Forecasts and trends
Pharmaceutical industry -- Forecasts and trends
Drug approval
Market trend/market analysis
Biotechnology industry
Business
Pharmaceuticals and cosmetics industries
Dupixent (Medication)
Ocrevus (Medication)
Subjects
Details
- Language :
- English
- ISSN :
- 1542166X
- Volume :
- 31
- Issue :
- 3
- Database :
- Gale General OneFile
- Journal :
- Biopharm International
- Publication Type :
- Periodical
- Accession number :
- edsgcl.536255770